We can’t show the full text here under this license. Use the link below to read it at the source.
Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East‐Asian patients with type 2 diabetes in a multicentre, double‐blind, randomized, parallel‐arm, active comparator, phase III trial
Dulaglutide alone compared with glimepiride for safety and effectiveness in East-Asian adults with type 2 diabetes
AI simplified
Abstract
A total of 737 patients were randomized, showing that dulaglutide significantly improved blood sugar control compared to glimepiride.
- Both doses of dulaglutide (1.5 mg and 0.75 mg) reduced glycated hemoglobin () more effectively than glimepiride.
- The least squares mean difference for HbA1c reduction was -6.34 mmol/mol (or -0.58%) for dulaglutide 1.5 mg and -3.50 mmol/mol (or -0.32%) for dulaglutide 0.75 mg.
- 74.1% of patients on dulaglutide 1.5 mg reached the HbA1c target of <53 mmol/mol (<7.0%), compared to 57.4% on glimepiride.
- Mean body weight decreased in patients taking dulaglutide, and total hypoglycemia rates were lower than in the glimepiride group.
- Common side effects in the dulaglutide groups included diarrhea, nausea, and decreased appetite.
AI simplified
Key numbers
-6.34 mmol/mol
Reduction with Dulaglutide 1.5 mg
Least squares mean difference from baseline at week 26.
74.1%
Target Achievement
Proportion of patients achieving <53 mmol/mol at week 26.
0.14 events/patient/year
Total Hypoglycemia Rates
Mean rates in the dulaglutide 1.5 mg group.